Pre-made Aprutumab benchmark antibody ( Whole mAb ADC, anti-FGFR2 therapeutic antibody, Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-031

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-031 Category Tag

Product Details

Pre-Made Aprutumab biosimilar, Whole mAb ADC, Anti-FGFR2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Aprutumab Ixadotin is an antibody-drug conjugate (ADC) directed against the fibroblast growth factor receptor type 2 (FGFR2) and conjugated to an as of yet unidentified toxin, with potential antineoplastic activity. Upon intravenous administration, aprutumab ixadotin binds to FGFR2.

Products Name (INN Index)

Pre-Made Aprutumab biosimilar, Whole mAb ADC, Anti-FGFR2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody

INN Name

Aprutumab

Target

FGFR2

Format

Whole mAb ADC

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Lambda

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2016

Companies

Bayer

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Solid tumours

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

FGFR2

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide